Dr. Russell J Schilder, MD
Claim this profileThomas Jefferson University
Studies Ovarian Cancer
Studies Endometrioid Carcinoma
10 reported clinical trials
16 drugs studied
Area of expertise
1Ovarian Cancer
Stage IV
PD-L1 positive
Stage III
2Endometrioid Carcinoma
Stage IV
PD-L1 positive
Stage III
Affiliated Hospitals
Clinical Trials Russell J Schilder, MD is currently running
Ipatasertib + Megestrol Acetate
for Endometrial Cancer
This trial is testing if combining two drugs, ipatasertib and megestrol acetate, is more effective than using megestrol acetate alone for treating women with endometrial cancer that has returned or spread. Ipatasertib blocks enzymes needed for cancer cell growth, while megestrol acetate reduces and blocks estrogen, which some cancer cells need to grow.
Recruiting1 award Phase 1 & 2
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
More about Russell J Schilder, MD
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Russell J Schilder, MD has experience with
- STRO-002
- Ipatasertib
- TAB004
- Toripalimab
- Bevacizumab
- Luveltamab Tazevibulin
Breakdown of trials Russell J Schilder, MD has run
Ovarian Cancer
Endometrioid Carcinoma
Fallopian Tube Cancer
Ovarian Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Russell J Schilder, MD specialize in?
Russell J Schilder, MD focuses on Ovarian Cancer and Endometrioid Carcinoma. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are PD-L1 positive.
Is Russell J Schilder, MD currently recruiting for clinical trials?
Yes, Russell J Schilder, MD is currently recruiting for 6 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Russell J Schilder, MD has studied deeply?
Yes, Russell J Schilder, MD has studied treatments such as STRO-002, Ipatasertib, TAB004.
What is the best way to schedule an appointment with Russell J Schilder, MD?
Apply for one of the trials that Russell J Schilder, MD is conducting.
What is the office address of Russell J Schilder, MD?
The office of Russell J Schilder, MD is located at: Thomas Jefferson University, Philadelphia, Pennsylvania 19107 United States. This is the address for their practice at the Thomas Jefferson University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.